Laetitia Marty

This study identifies the Fra-2-NF-κB-IL-1β axis as a mechanism driving chemoresistance in Tax-negative ATL, with therapeutic targeting of IL-1 signaling restoring drug sensitivity.

This paper introduces a new HIV-1 latency reversing agent, D10, which activates HIV-1 Tat to induce viral production from latent cells.

This paper identifies HBZ splicing regulation by hnRNPA1 and hnRNPH1 as a key driver of HTLV-1 leukemogenesis, showing that HBZ_SP1 promotes transformation and chemoresistance in ATL.